RxDoctor Payments Data

Paige Reese, OD

Optometrist · Antioch, TNNPI 1205357563

Payments from drug & device makers

$1,028in general payments, 2019–2025

Across 18 payments — averaging $57.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb, A Division Of Bausch Health US, LLC$249
  • Carl Zeiss Meditec, Inc.$196
  • Coopervision Inc.$168
  • Novartis$122
  • Alcon$109
  • Johnson & Johnson Vision Care, Inc.$108
  • plus $75 from 2 others

What the payments were for

  • Food & beverage$1,028100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,028 in reported general payments places this provider in the 60th percentile of 1,122 optometrist providers in Tennessee.

See all optometrist providers in Tennessee

Medicare billing

Part B allowed, 2024
$157,102
Medicare patients
590
Services billed
7,921

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost50$17,218
XiidraLifitegrast19$17,134
Alphagan PBrimonidine Tartrate23$6,003
Travoprost39$4,561
Cyclosporine12$1,738
Brimonidine Tartrate31$1,506
Brinzolamide12$1,436
Latanoprost198$1,229
Prednisolone Acetate40$1,166
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat44$1,157
Tobramycin-DexamethasoneTobramycin/Dexamethasone14$725
Timolol Maleate51$335
Dorzolamide Hcl20$296
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha26$242
ErythromycinErythromycin Base19$167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$29$17,13419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,122 optometrist providers in Tennessee.

Other optometrist in Antioch

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →